Quarterly ResultApr 30, 2026, 06:22 AM
ADXN Reports FY25 Net Loss CHF 6.7M; Advances Pipeline
AI Summary
Addex Therapeutics reported a net loss of CHF 6.7 million for the full year 2025, a significant decrease from a net profit of CHF 7.1 million in 2024, primarily due to the consideration received from the Neurosterix transaction in 2024. The company ended the year with CHF 1.6 million in cash and cash equivalents. Operationally, Addex advanced its GABAB PAM chronic cough candidate, repositioned dipraglurant for brain injury recovery with a new collaboration agreement with Sinntaxis, and regained rights to its mGlu2 PAM asset, ADX71149. Partner Indivior also progressed its GABAB PAM program, and Addex made a strategic investment in Stalicla SA.
Key Highlights
- ADXN reported a net loss of CHF 6.7 million for 2025, compared to a net profit of CHF 7.1 million in 2024.
- Cash and cash equivalents stood at CHF 1.6 million at December 31, 2025.
- Income from continuing operations decreased to CHF 0.2 million in 2025 from CHF 0.4 million in 2024.
- R&D expenses from continuing activities decreased by CHF 0.2 million in 2025.
- GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity.
- Entered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property for mGlu5 NAM in brain injury recovery.
- Regained rights to phase 2 mGlu2 PAM asset, ADX71149, adding a second Phase 2 clinical asset.
- Partner Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies.
- Made a strategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disorders.